First Financial Corp IN lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 7.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 52,009 shares of the biopharmaceutical company’s stock after selling 4,215 shares during the quarter. Pfizer accounts for 1.2% of First Financial Corp IN’s portfolio, making the stock its 13th largest position. First Financial Corp IN’s holdings in Pfizer were worth $1,884,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of the business. Gofen & Glossberg LLC IL lifted its holdings in shares of Pfizer by 0.7% in the 4th quarter. Gofen & Glossberg LLC IL now owns 480,157 shares of the biopharmaceutical company’s stock valued at $17,391,000 after buying an additional 3,213 shares during the period. Pennsylvania Trust Co acquired a new position in shares of Pfizer in the 4th quarter valued at about $22,749,000. Atria Investments LLC lifted its holdings in shares of Pfizer by 12.3% in the 4th quarter. Atria Investments LLC now owns 234,610 shares of the biopharmaceutical company’s stock valued at $8,498,000 after buying an additional 25,728 shares during the period. Hexavest Inc. lifted its holdings in shares of Pfizer by 1.9% in the 4th quarter. Hexavest Inc. now owns 6,927,838 shares of the biopharmaceutical company’s stock valued at $250,926,000 after buying an additional 129,181 shares during the period. Finally, Daiwa SB Investments Ltd. lifted its holdings in shares of Pfizer by 25.2% in the 4th quarter. Daiwa SB Investments Ltd. now owns 8,540 shares of the biopharmaceutical company’s stock valued at $309,000 after buying an additional 1,720 shares during the period. Institutional investors and hedge funds own 71.41% of the company’s stock.
Shares of Pfizer Inc. (PFE) opened at $36.61 on Tuesday. Pfizer Inc. has a 52 week low of $31.67 and a 52 week high of $39.43. The company has a current ratio of 1.35, a quick ratio of 1.10 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $217,930.00, a P/E ratio of 20.92, a price-to-earnings-growth ratio of 2.07 and a beta of 0.91.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd were paid a dividend of $0.34 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 annualized dividend and a yield of 3.71%. The ex-dividend date was Thursday, February 1st. Pfizer’s payout ratio is 77.71%.
Pfizer announced that its board has initiated a share repurchase plan on Monday, December 18th that authorizes the company to repurchase $10.00 billion in shares. This repurchase authorization authorizes the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board of directors believes its shares are undervalued.
A number of equities analysts recently weighed in on the company. BMO Capital Markets set a $43.00 price target on Pfizer and gave the stock a “buy” rating in a report on Tuesday, March 6th. Jefferies Group set a $39.00 price target on Pfizer and gave the stock a “hold” rating in a report on Monday, February 26th. Berenberg Bank set a $36.00 price target on Pfizer and gave the stock a “neutral” rating in a report on Tuesday, January 30th. UBS Group set a $42.00 price target on Pfizer and gave the stock a “buy” rating in a report on Wednesday, January 31st. Finally, Leerink Swann upped their price target on Pfizer from $35.00 to $38.00 and gave the stock a “market perform” rating in a report on Wednesday, January 31st. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company. Pfizer presently has an average rating of “Hold” and an average target price of $39.40.
In other news, insider Charles H. Hill sold 42,393 shares of the company’s stock in a transaction that occurred on Tuesday, March 6th. The stock was sold at an average price of $35.76, for a total value of $1,515,973.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mikael Dolsten sold 69,699 shares of the company’s stock in a transaction that occurred on Friday, March 9th. The shares were sold at an average price of $36.59, for a total value of $2,550,286.41. Following the completion of the sale, the insider now owns 120,784 shares of the company’s stock, valued at $4,419,486.56. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 185,464 shares of company stock valued at $6,767,939. 0.06% of the stock is owned by company insiders.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.